Exclusive

Publication

Byline

Singapore Clinical Trial: EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate... Read More


Singapore Clinical Trial: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metast... Read More


Singapore Clinical Trial: RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Pa... Read More


Singapore Clinical Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients with Severe Chronic Kidney Disease

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiov... Read More


Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More


Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More


Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More


Singapore Clinical Trial: An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BAY 3771249 as monotherapy or combination with other cancer treatments in participants with solid tumors harboring a KRAS G12D mutation

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and... Read More


Singapore Clinical Trial: A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation.

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asci... Read More